Abstract
A clinical decision report using:
Orkin C, Molina JM, Negredo E, et al. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV. 2018;5(1):e23-e34. https://doi.org/10.1016/S2352-3018(17)30179-0
for a patient with viriologically suppressed HIV-1.
DOI
10.22237/crp/1625097720
Creative Commons License
This work is licensed under a Attribution 4.0 International (CC-BY 4.0) License
Recommended Citation
KATHURIA P. Using a single tablet regimen of darunavir, cobicistat, emcitrabine, and tenofovir alafenamide in virally suppressed HIV-1 patients is an adequate treatment option for controlling HIV. Clin. Res. Prac. Oct 13 2021;7(2):eP2531. https://doi.org/10.22237/crp/1625097720
Included in
Family Medicine Commons, Infectious Disease Commons, Internal Medicine Commons, Medical Education Commons, Virus Diseases Commons
